Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles.
The potential of multilamellar vesicles (MLVs) as carriers of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) (CPDP), a lipophilic cisplatin derivative, was assessed. MLVs composed of dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), and cholesterol at different molar ratios were tested. The MLV-CPDP preparation with the highest antitumor activity against L1210 leukemia in vivo was DMPC:DMPG 7:3-CPDP. The encapsulation efficiency of this preparation was 66 +/- 4% (SD); the stability in 0.9% NaCl solution at 4 degrees C was 89% at 14 days and 93% 18 h after incubation in human AB serum at 37 degrees C. The toxicities of DMPC:DMPG 7:3-CPDP and free CPDP (suspended in hydroxypropyl cellulose) administered i.p. were similar (50% lethal dose = 75 versus 91 mg/kg; blood urea nitrogen values 96 h after the administration of the 50% lethal dose = 32.0 versus 34.4 mg/dl). The mean %T/C [(median survival time of treated mice divided by median survival time of control mice) X 100] obtained after a single i.p. injection of the optimal dose of each preparation tested was 215 (range 200 to 232) for DMPC:DMPG 7:3-CPDP, 175 (range 158 to 209) for DMPG-CPDP, 162 (range 136 to 179) for free CPDP, and 178 (range 169 to 189) for cisplatin. Using a multiple i.p. injection schedule (injections on Days 1, 5, and 9), DMPC:DMPG 7:3-CPDP was more active than free CPDP and cisplatin (%T/C: 403, 284, and 253% respectively). DMPC:DMPG 7:3-CPDP is less toxic and more active against L1210 leukemia in vivo than is cisplatin. The encapsulation of CPDP in MLVs composed of DMPC:DMPG 7:3 provides an adequate vehicle for the administration of this lipophilic compound and enhances its antitumor activity against L1210 leukemia.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D004134:Dimyristoylphosphatidylcholine / Q000032:analysis; D004355:Drug Stability; D007668:Kidney / Q000187:drug effects; D007939:Leukemia L1210 / Q000188:drug therapy / Q000473:pathology; D008081:Liposomes / Q000008:administration & dosage* / Q000032:analysis; D051379:Mice; D008815:Mice, Inbred Strains; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D014677:Pharmaceutical Vehicles; D010715:Phosphatidylglycerols / Q000032:analysis
D000970:Antineoplastic Agents; D008081:Liposomes; D009944:Organoplatinum Compounds; D014677:Pharmaceutical Vehicles; D010715:Phosphatidylglycerols; C050540:bis(cyclopentenecarboxylato)-1,2-diaminocyclohexane-platinum(II); C002773:dimyristoylphosphatidylglycerol; D004134:Dimyristoylphosphatidylcholine